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Abstract 
Purpose: To identify the frequency, levels and predictors of potential drug-drug interactions (pDDIs) in 
a pediatrics ward of a teaching hospital in Pakistan. 
Methods: Medication profiles of 400 pediatric patients were evaluated for pDDIs using Micromedex 
Drug-Reax® software. Logistic regression was used to identify association of pDDIs with hospital-stay, 
patient’s gender, and number of medications. 
Results: In total, 86 interacting drug-combinations resulting in 260 pDDIs were identified. Overall, 25.8 
% patients were exposed to at least one pDDI regardless of severity-type, 10.7 % to at least one major-
pDDI, 15.2 % to at least one moderate-pDDI, and 12.5 % to at least one minor-pDDI. Of 260 pDDIs, 
most were of moderate severity (41.5 %) followed by minor (35.4 %) and major severity (21.9 %); good 
(76.9 %) or fair (16.5 %) type of scientific evidence; and delayed onset (46.5 %). Some widespread 
major or moderate interactions included rifampin + pyrazinamide (14 cases), phenobarbital + diazepam 
(14), dexamethasone + rifampin (8), amikacin + furosemide (7), furosemide + captopril (7), 
dexamethasone + phenobarbital (6), phenobarbital + divalproex sodium (6), isoniazid + rifampin (5) 
amikacin + ibuprofen (5), digoxin + furosemide (4), and acetaminophen + phenytoin sodium (4). There 
was significant association of the occurrence of pDDIs with five or more prescribed medications (p < 
0.001).   
Conclusion: PDDIs are less prevalent in the pediatrics ward of the hospital studied. Most of the 
interactions were of moderate severity. Patients with increased number of prescribed medications were 
more exposed to these interactions. 
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Recent developments in pharmacotherapy have 
contributed considerably to improve patients’ 
quality of life. As a result of such advancement, 
the number of available medications and their 
uses are increasing. Although drugs are used to 
achieve beneficial therapeutic effects, they can 
also lead to many undesirable consequences. 
One of such consequences is the problem of 
potential drug-drug interactions (pDDIs) that may 
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lead to alteration of therapeutic response or 
increase in untoward effects of many drugs [1,2]. 
 
A wide variation exists in the prevalence of 
pDDIs in hospital settings due to differences in 
the design of research studies. Prevalence of 
pDDIs has been reported in the range of 19.3 
to 88.8 % [3,4]. A study, conducted in two 
hospitals in England, found that 1225 (6.5 %) 
hospital-admissions were caused by medicines, 
of which, 203 (16.6 % of 1225) admission were 
related to drug-interactions [5]. A review paper 
analyzed published literature related to drug 
related problems (DRPs) in hospitals. It was 
reported that during hospitalization, 17 % of all 
adverse drug events are caused by drug-drug 
interactions [6]. 
 
Some studies have investigated pDDIs in 
particular clinical situations or specialties such as 
cardiology [7], oncology [8], psychiatry [9], 
intensive care units [10], pulmonology [11], and 
geriatrics [12]. Most of the aforementioned 
studies are limited to adult patients. To the best 
of our knowledge, such data are scarce in 
pediatrics specialty. It has been pointed out that 
hospitalized pediatrics patients are at higher risk 
to drug-induced problems because of many 
factors such as wide-ranging of patient ages and 
body-weights, limited physiologic reserve, 
calculation errors in medications dosing, and 
incapability to properly communicate with 
healthcare professionals [13]. In such 
circumstances, pDDIs are more likely to cause 
adverse outcomes in pediatrics hospitalized 
patients. Therefore, studies are obligatory to 
report data regarding pDDIs in such an important 
population. 
 
The present study aimed to find prevalence and 
levels of pDDIs in a pediatrics ward; their 
association with length of hospital-stay, patients’ 
gender, and number of prescribed medications; 





This study was carried out in pediatrics ward of 
Khyber Teaching Hospital, Peshawar, Pakistan, 
which is a 1200-bed teaching hospital. The 
hospital is a busy health care center along with 
referral services. It serves a population of about 
350 thousand inhabitants of Jamrud Road and 
adjacent areas of Peshawar district. 
 
The study was approved by Ethical Committee of 
the Department of Pharmacy, University of 
Peshawar. A cross-sectional design was used 
which involved evaluation of medical records of 
400 patients admitted during the month of May - 
July 2011. Hospitalized patients, < 18 years old, 
suffering from any type of disease, and both 
males and females were included in this study. 
Permission was obtained from hospital 
administration to carry out this study in hospital. 
The following information items were collected: 
patient’s age, gender, date of admission, date of 
discharge, diagnosis and detail of medication 
therapy provided in the hospital. All regular and 
PRN (pro-re-nata, means as required) 
medications were included, however, topical 
products such as creams, ointments, eye drops 
and ear drops were excluded from analysis. 
 
Micromedex Drug-Reax® Software (Thomson 
Reuters Healthcare Inc., Greenwood Village, 
Colorado, United States) [14], was used to 
screen patients’ medication profiles for pDDIs. 
The software displays all drug-interactions 
present in the patient’s profile. As per 
classification of Micromedex Drug-Reax® 
System [14], all identified-pDDIs were 
categorized on the basis of their levels of 




• Rapid: The effect of interaction occurs within 
24 hours of administration.  
• Delayed: The effect occurs if the interacting 
combination is administered for more than 24 
h, i.e., days to week(s). 
Severity  
• Contraindicated: The drug-combination is 
contraindicated for concurrent use. 
• Major: There is risk of death and/or medical 
intervention is required to prevent or 
minimize serious negative outcomes. 
• Moderate: The effect of interaction can 
deteriorate patient’s condition and may 
require alteration of therapy. 
• Minor: Little effects are produced that don’t 
impair therapeutic outcome and there is no 
need of any major change in therapy 
Scientific evidence (Documentation) 
• Excellent: The interaction has been clearly 
demonstrated in well-controlled studies. 
• Good: Studies strongly suggest that the 
interaction exists except proof of well-
controlled studies. 
• Fair: Available evidences are poor, but the 
interaction is suspected on the basis of 
pharmacologic considerations; or, evidences 
are good for an interaction of 
pharmacologically similar drug. 
• Poor: Theoretically, the interaction may 
occur but reports are very limited, such as 
few case reports. 
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• Unlikely: Data are very poor and lack a 
proper pharmacologic basis. 
 
Prevalence of pDDIs, belong to any of the 
severity-levels (overall-prevalence), was 
identified. Likewise, number of patients exposed 
to different types of pDDIs such as 
contraindicated-pDDIs, major-pDDIs, moderate-
pDDIs and minor-pDDIs, were determined. All 
identified pDDIs were categorized on the basis of 





Quantitative variables such as age, hospital stay 
and number of prescribed medications are 
presented as median and ranges. Categorical 
variables such as gender, prevalence and levels 
of pDDIs are presented as frequencies and 
percentages. Logistic regression technique was 
used to determine the association of occurrence 
of one or more pDDIs with length of hospital stay, 
patients’ gender, and number of prescribed 
medications. In the model, exposure to potential 
drug-drug interactions (pDDIs) was the 
dependent variable (0 = absent, 1 = present). 
Whereas, the following variables were included 
as predictors of pDDIs: length of hospital stay (1 
= less than 5 days, 2 = 5 days or above), 
patient’s gender (1 = female, 2 = male), and 
number of prescribed medications (1 = less than 
5, 2 = 5 or above). Initially a univariate analysis 
was performed followed by multivariate analysis, 
in which, variables with univariate p-values < 0.1 
were included. The Hosmer–Lemeshow test was 
used to assess goodness-of-fit of the logistic 
regression model. P-value of 0.05 or less was 
considered statistically significant. SPSS for 
Windows version 16 (SPSS, Inc., Chicago, IL, 




Of the total 400 patients, 254 (63.5 %) were 
males and 146 (36.5 %) were females. Median 
age was 1.5 years, median hospital stay was four 
days and median number of prescribed 
medications were four (Table 1). One hundred 
and three (25.8 %) had at least one pDDI 
regardless of type of severity (Table 2). As far as 
prevalence of pDDIs on the basis of severity was 
concerned, moderate pDDIs were most prevalent 
and recorded in 15.2 % patients followed by 
minor pDDIs (12.5 %). 
 
The levels of onset, severity and scientific 
evidence (documentation) for the identified 
pDDIs are given in Table 3. Of 260 pDDIs, most 
were of moderate severity (41.5%) followed by 
minor (35.4%) and major severity (21.9%); good 
(76.9%) or fair (16.5%) type of scientific 
evidence; and delayed onset (46.5%).  
 
Table 1: General characteristics of patients in 
the pediatric ward 
 


















Median    -   1.5 years 
Range - 1 month-17 years 
 







Median     -      4 











Median      -     4 
Range       -      1-15 
 
 
Table 2: Prevalence of potential drug-drug 
interactions in a pediatric ward 
 
Type of prevalence Patients:  n (%) 




















Median       -      1 
Range        -       1-12 
 
- PDDIs = Potential drug-drug interactions 
-* Overall prevalence means presence of at least 
one pDDIs regardless of severity-type  
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Table 3: Levels of potential drug-drug 










n (%) n (%) 



































- PDDIs = Potential drug-drug interactions 
-* In pediatric ward, 86 interacting drug-combinations 
were identified that encountered in total number of 260 
pDDIs. 
 
In this study, 86 potential interacting drug-
combinations were identified. The top 14 
frequently occurring interacting drug-pairs 
included four major, seven moderate and three 
minor types of pDDIs. These 14 interacting drug-
pairs encountered in 155 pDDIs (59.6% of 260), 
while rest of 72 interacting drug-pairs presented 
in the remaining 40.3% pDDIs. Frequencies of 
some widespread interacting drug-combinations 
are given in Table 4.  
 
In univariate logistic regression analysis (Table 
5), there was significant association of the 
occurrence of pDDIs with hospital stay of five 
days or longer (OR = 1.92; 95 % CI = 1.21-3.04; 
p < 0.01), female gender (OR for male = 0.63; 95 
% CI = 0.39-0.99; p = 0.047), and five or more 
number of prescribed medications (OR = 7.34; 
95 % CI = 4.37-12.32; p < 0.001). In multivariate 
analysis (Table 5), association was significant 
only in case of five or more number of prescribed 





In the present study, prevalence and nature of 
pDDIs have been reported in 400 pediatric 
hospitalized patients. Total 86 interacting drug-
combinations were identified that encountered in 
260 pDDIs. Overall, 25.8 % patients were 
exposed to at least one pDDI regardless of 
severity-types, 10.75 % to at least one major 
pDDI, 15.25 % to at least one moderate pDDI, 
and 12.5 % to at least one minor pDDI. In 
comparison to other clinical settings, overall 
prevalence of pDDIs in pediatrics (25.8 %) was 
lower than that reported by many other studies 
ranging from 37 % to 50% in whole hospital 
settings [15,16]; 77.5 % in cardiology [7], 48 % in 
internal medicine [17], 58 % in oncology [8], 64.8 
% in psychiatry [9], 70 % in intensive care units 
[10], and 45 % in pulmonology [11]. Results of 
the present study suggest that pDDIs are less 
prevalent in pediatrics ward as compared with 
other wards and specialties such as cardiology, 
internal medicine, oncology, psychiatry, intensive 
care units and pulmonology. 
 




Major interactions  
Rifampin + pyrazinamide 14 
Phenobarbital + diazepam 14 
Amikacin + furosemide 7 
Isoniazid + rifampin 5 
Quinine + rifampin 3 
Artemether/lumefantrine + quinine 3 
Calcium carbonate + digoxin  2 
Theophylline + ciprofloxacin 2 
Moderate interactions  
Dexamethasone + rifampin 8 
Furosemide + captopril 7 
Phenobarbital + divalproex sodium 6 
Dexamethasone + phenobarbital 6 
Amikacin + ibuprofen 5 
Digoxin + furosemide 4 
Acetaminophen + phenytoin sodium  4 
Phenytoin sodium + diazepam 3 
Furosemide + ibuprofen 3 
Dexamethasone + phenytoin sodium  3 
Ciprofloxacin + zinc  3 
Rifampin + divalproex sodium 3 
Minor interactions  
Amikacin + cloxacillin sodium 35 
Amikacin + ampicillin 35 
Phenytoin sodium + phenobarbital 5 
Iron + antacid 3 
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Table 5: Logistic regression analysis 
 
Patients: n  Univariate  Multivariate 
Variable Interaction 
present 
(n = 103 ) 
Interaction 
absent 
(n = 297 ) 
 





Hospital stay (days)  
 




















0.99)    0.047 
0.74 (0.45-
1.23) 0.246 
Number of drugs   
 











-OR = Odds ratio; CI = Confidence interval. 
- Exposure to potential drug-drug interactions (pDDIs) was the dependent variable in the model (0 = absent, 1 = 
present). The following variables were included in the model as predictors of pDDIs: hospital stay (1 = less than 
5 days, 2 = 5 days or above), patient’s gender (1 = female, 2 = male), and number of drugs (1 = less than 5, 2 = 
5 or above).  
-Hosmer–Lemeshow goodness-of-fit test: p = 0.87 
 
As far as levels of pDDIs are concerned, our 
study shows that most of the interactions were of 
moderate severity (41.5 %) followed by minor 
(35.4 %) and major severity (21.9 %); good (76.9 
%) or fair (16.5 %) type of scientific evidence; 
and delayed onset (46.5%). Similar findings have 
been reported by other studies, conducted in 
other wards or specialties [17,18]. A study 
identified total 402 pDDIs in clinical records of 
500 patients, of which, most were of moderate 
severity (70 %), good scientific evidences 
(69.4 %) and delayed onset (89.8 %) [17].  
 
Clinical records of 407 patients were evaluated 
for pDDIs. Total 276 pDDIs were identified, of 
which, most pDDIs were having moderate 
severity (77 %) and good scientific evidences 
(40 %) [18]. The aforementioned discussion 
shows that results of our study are consistent 
with published literature. Moreover, the list of 
interacting drug-combinations, particularly 
widespread major and moderate interactions, will 
be helpful for health care professionals to screen 
patients’ profiles for pDDIs. This will improve 
practice regarding the management of pDDIs in 
clinical settings. 
 
The results of this study show that patients with 
five or more number of prescribed medications 
were found to be more exposed to pDDIs (OR = 
6.82; 95 % CI = 4.0-11.59; p < 0.001). These 
results are in agreement with many other 
published reports [3,8,10,12,15,18]. It is 
recommended that patients with increased 
number of medications should be properly 
monitored for pDDIs in order to prevent and 
minimize the negative consequences of these 
interactions. 
 
Limitations of the study 
 
In the present study, only potential drug-drug 
interactions were investigated. Further work will 
be required to identify the actual effects of these 
interactions. This study was conducted in a 
tertiary care hospital of Khyber Pakhtunkhwa 
province of Pakistan. Therefore, the findings may 
not be generalizable to hospitals elsewhere in 
Pakistan. However, we expect a similar pattern in 




PDDIs were less prevalent in pediatrics ward. 
Most of the interactions were of moderate 
severity. Patients with increased number of 
prescribed medications were more exposed to 
these interactions. Due to sensitive nature of 
pediatric population, close monitoring is 
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